Burning and Scaling Probably Associated with Dupilumab Therapy: A Case Report

CASE REPORT: We present the case of a 51-year-old male who experienced temporary desquamation and recurrent burning sensation in primary skin lesions after the injection of dupilumab. The scaling lasted for 1 week and subsided, while the burning became aggravated with each injection of dupilumab, wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Nana, Wang, Qiuyue, Lei, Min, Li, Zhiyong, Li, Tianhao, Hao, Pingsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393013/
https://www.ncbi.nlm.nih.gov/pubmed/36000004
http://dx.doi.org/10.2147/CCID.S373997
Descripción
Sumario:CASE REPORT: We present the case of a 51-year-old male who experienced temporary desquamation and recurrent burning sensation in primary skin lesions after the injection of dupilumab. The scaling lasted for 1 week and subsided, while the burning became aggravated with each injection of dupilumab, which gradually subsides after 8 weeks, and there was no recurrence since then. CONCLUSION: Dupilumab is an emerging and efficacious biologics medication for AD. The burning sensation and scaling we report may be the adverse events of dupilumab. Rare adverse reactions to biologics deserve the attention of physicians.

Ejemplares similares